- Conditions
- Anal Cancer, Neoplasm of Uncertain Malignant Potential, Nonneoplastic Condition, Precancerous Condition
- Interventions
- clinical observation, infrared photocoagulation therapy
- Other · Device
- Lead sponsor
- AIDS Malignancy Consortium
- Network
- Eligibility
- 27 Years and older
- Enrollment
- 120 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2011 – 2016
- U.S. locations
- 7
- States / cities
- Los Angeles, California • San Francisco, California • Boston, Massachusetts + 3 more
Search Results
Search by objective public record fields.
Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results are retrieved from ClinicalTrials.gov and synchronized into the directory. Search pages remain noindex by default.
Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.
Showing 1–24
of 450
matching trials from the live ClinicalTrials.gov search.
Local D1 index available.
- Conditions
- HPV Vaccine
- Interventions
- Intervention Arm
- Behavioral
- Lead sponsor
- University of California, Davis
- Other
- Eligibility
- 10 Years to 12 Years
- Enrollment
- 2,232 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2025 – 2026
- U.S. locations
- 1
- States / cities
- Sacramento, California
- Conditions
- Verruca (Warts)
- Interventions
- Occlusive Heat Patch
- Device
- Lead sponsor
- Yale University
- Other
- Eligibility
- 5 Years and older
- Enrollment
- 73 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2012 – 2019
- U.S. locations
- 1
- States / cities
- New Haven, Connecticut
- Conditions
- Human Papillomavirus Infection
- Interventions
- Assessment Feedback Incentives and eXchange, Physician-to-physician engagement, Active Intervention Control
- Other
- Lead sponsor
- University of North Carolina, Chapel Hill
- Other
- Eligibility
- Not listed
- Enrollment
- 264 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2018 – 2020
- U.S. locations
- 3
- States / cities
- Phoenix, Arizona • Albany, New York • Madison, Wisconsin
- Conditions
- HPV Vaccination
- Interventions
- General HPV Vaccine Health Messaging, Culturally Targeted HPV Vaccine Health Messaging
- Behavioral
- Lead sponsor
- Michigan State University
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 265 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2024 – 2026
- U.S. locations
- 1
- States / cities
- Flint, Michigan
- Conditions
- Head and Neck Cancer, Precancerous Condition
- Interventions
- cetuximab, intensity-modulated radiation therapy (IMRT), Paclitaxel, Cisplatin
- Biological · Radiation · Drug
- Lead sponsor
- Eastern Cooperative Oncology Group
- Network
- Eligibility
- 18 Years and older
- Enrollment
- 90 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2010 – 2015
- U.S. locations
- 121
- States / cities
- Birmingham, Alabama • Greenbrae, California • Palo Alto, California + 86 more
- Conditions
- Human Papilloma Virus Infection, Stage III Squamous Cell Carcinoma of the Oropharynx, Stage IVA Squamous Cell Carcinoma of the Oropharynx, Stage IVB Squamous Cell Carcinoma of the Oropharynx
- Interventions
- paclitaxel albumin-stabilized nanoparticle formulation, carboplatin, radiation therapy, paclitaxel, fluorouracil, hydroxyurea, cisplatin, laboratory biomarker analysis, quality-of-life assessment
- Drug · Radiation · Other + 1 more
- Lead sponsor
- University of Chicago
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 62 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2014 – 2024
- U.S. locations
- 1
- States / cities
- Chicago, Illinois
- Conditions
- Genital Warts
- Interventions
- 2.5% imiquimod cream, 3.75% imiquimod cream, Placebo cream
- Drug
- Lead sponsor
- Graceway Pharmaceuticals, LLC
- Industry
- Eligibility
- 12 Years and older
- Enrollment
- 511 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2008 – 2009
- U.S. locations
- 43
- States / cities
- Jonesboro, Arkansas • Carmichael, California • Chico, California + 35 more
- Conditions
- Human Papilloma Virus, HPV, Post Partum
- Interventions
- Not listed
- Lead sponsor
- Columbia University
- Other
- Eligibility
- 18 Years to 26 Years · Female only
- Enrollment
- 150 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2009 – 2012
- U.S. locations
- 1
- States / cities
- New York, New York
- Conditions
- Human Papillomavirus
- Interventions
- Cohort: 3000 men examined every 6 months for 4 years., Pilot study: 150 men examined every 6 months for 4 years.
- Other
- Lead sponsor
- H. Lee Moffitt Cancer Center and Research Institute
- Other
- Eligibility
- 18 Years to 70 Years · Male only
- Enrollment
- 1,431 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2005 – 2014
- U.S. locations
- 1
- States / cities
- Tampa, Florida
- Conditions
- Gynecologic Cancer
- Interventions
- Receive routine instructions, Telehealth-based instructional visit and receive routine instructions
- Other
- Lead sponsor
- OHSU Knight Cancer Institute
- Other
- Eligibility
- 25 Years to 85 Years · Female only
- Enrollment
- 131 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2022 – 2023
- U.S. locations
- 1
- States / cities
- Portland, Oregon
- Conditions
- Human Papillomavirus-Related Cervical Carcinoma
- Interventions
- Non-Interventional Study
- Other
- Lead sponsor
- Mayo Clinic
- Other
- Eligibility
- 18 Years to 65 Years · Female only
- Enrollment
- 100 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2026 – 2027
- U.S. locations
- 1
- States / cities
- Jacksonville, Florida
- Conditions
- HPV-Related Squamous Cell Carcinoma
- Interventions
- HB-201 intravenous administration., HB-202 intravenous administration alternating with HB-201 intravenous administration., HB-201 intravenous administration + standard of care regimen including pembrolizumab., HB-202 / HB-201 alternating intravenous administration + pembrolizumab., HB-202 / HB-201 alternating intravenous administration + standard of care regimen including pembrolizumab., HB-201 or HB-201/HB-202 alternating treatment using CD8 PET Tracer (Zr-Df-IAB22M2C)
- Drug
- Lead sponsor
- Hookipa Biotech GmbH
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 198 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2019 – 2025
- U.S. locations
- 26
- States / cities
- Birmingham, Alabama • Gilbert, Arizona • Fayetteville, Arkansas + 19 more
- Conditions
- N/A - Healthy Subjects
- Interventions
- short videos related to HPV and the HPV vaccine, CDC HPV Fact Sheet
- Other
- Lead sponsor
- Michigan State University
- Other
- Eligibility
- 18 Years to 26 Years
- Enrollment
- 123 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2024 – 2026
- U.S. locations
- 1
- States / cities
- East Lansing, Michigan
- Conditions
- Human Papillomavirus (HPV)-Positive Oropharyngeal Cancer
- Interventions
- Cisplatin, Postoperative radiotherapy
- Drug · Radiation
- Lead sponsor
- Lisette Nixon
- Government
- Eligibility
- 18 Years and older
- Enrollment
- 1,269 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2015 – 2028
- U.S. locations
- 3
- States / cities
- Redwood City, California • Orlando, Florida • Houston, Texas
- Conditions
- HSIL, High-Grade Squamous Intraepithelial Lesions, Human Papilloma Virus Infection, HIV Infection, Anal Cancer, Anus Neoplasm
- Interventions
- Topical ABI-1968 cream
- Drug
- Lead sponsor
- Antiva Biosciences
- Industry
- Eligibility
- 27 Years and older
- Enrollment
- 6 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2018 – 2019
- U.S. locations
- 1
- States / cities
- Chicago, Illinois
- Conditions
- Anal Intraepithelial Neoplasia, High Grade Squamous Intraepithelial Neoplasia, HIV Positivity, Human Papillomavirus-16 Positive, Human Papillomavirus-18 Positive
- Interventions
- Electroporation, HPV DNA Plasmids Therapeutic Vaccine VGX-3100, Laboratory Biomarker Analysis
- Device · Biological · Other
- Lead sponsor
- AIDS Malignancy Consortium
- Network
- Eligibility
- 18 Years and older
- Enrollment
- 44 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2018 – 2025
- U.S. locations
- 7
- States / cities
- San Francisco, California • Atlanta, Georgia • Chicago, Illinois + 4 more
- Conditions
- Head and Neck Neoplasms
- Interventions
- Monalizumab, Cetuximab, Anti-PD(L)1
- Biological
- Lead sponsor
- Innate Pharma
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 143 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2015 – 2023
- U.S. locations
- 9
- States / cities
- La Jolla, California • Stanford, California • Chicago, Illinois + 5 more
- Conditions
- Cervical Cancer, Hpv, Warts
- Interventions
- Quadrivalent HPV for types 6, 11, 16 and 18
- Biological
- Lead sponsor
- Medstar Health Research Institute
- Other
- Eligibility
- 9 Years to 17 Years
- Enrollment
- 25 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2010 – 2012
- U.S. locations
- 2
- States / cities
- Washington D.C., District of Columbia
- Conditions
- Human Papillomavirus Vaccination
- Interventions
- Not listed
- Lead sponsor
- Indiana University
- Other
- Eligibility
- 13 Years to 17 Years
- Enrollment
- 62 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2011 – 2012
- U.S. locations
- 1
- States / cities
- Indianapolis, Indiana
- Conditions
- Cervical Intraepithelial Neoplasia
- Interventions
- CervImage device
- Device
- Lead sponsor
- Carilion Clinic
- Other
- Eligibility
- 21 Years to 70 Years · Female only
- Enrollment
- 18 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2025 – 2026
- U.S. locations
- 1
- States / cities
- Roanoke, Virginia
- Conditions
- Human Papilloma Virus Vaccine
- Interventions
- STOP-HPV-Online, STOP-HPV-LC
- Behavioral
- Lead sponsor
- University of California, Los Angeles
- Other
- Eligibility
- 9 Years to 17 Years
- Enrollment
- 100,000 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2026 – 2027
- U.S. locations
- 1
- States / cities
- Alexandria, Virginia
- Conditions
- Human Papillomavirus-Independent Cervical Adenocarcinoma, Clear Cell-Type
- Interventions
- Electronic Health Record Review, Laboratory Biomarker Analysis
- Other
- Lead sponsor
- M.D. Anderson Cancer Center
- Other
- Eligibility
- Female only
- Enrollment
- 70 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2021 – 2026
- U.S. locations
- 1
- States / cities
- Houston, Texas
- Conditions
- Cervical Cancer, Genital Warts
- Interventions
- Received HPV vaccine first, Received concomitant vaccines first
- Biological
- Lead sponsor
- Duke University
- Other
- Eligibility
- 9 Years to 18 Years · Female only
- Enrollment
- 72 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2009 – 2012
- U.S. locations
- 3
- States / cities
- Chapel Hill, North Carolina • Durham, North Carolina